News

Video

Managing Adverse Events in Patients Receiving Later Line Systemic Therapy for Metastatic TNBC

Author(s):

Nour Abuhadra, MD

Dr. Noor Abuhadra discusses managing adverse events in patients receiving TRODELVY (sacituzumab govitecan), a later-line systemic therapy for metastatic triple-negative breast cancer. Shay Elkins, a patient, shares her experience with significant side effects including diarrhea, low white blood cell counts, and hair loss, while Dr. Abuhadra emphasizes the need for proactive management of these issues to maximize treatment time and maintain quality of life.

Related Videos
Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer.
Dr. Debu Tripathy is a professor and chairman of the Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, in Houston, and the editor-in-chief of CURE®.
Dr. Azka Ali is a medical oncologist at the Cleveland Clinic Taussig Cancer Institute, in Ohio.
Dr. Maxwell Lloyd, a Clinical Fellow in Medicine in the Department of Medicine at Beth Israel Deaconess Medical Center in Boston.
Dr. Maxwell Lloyd, a Clinical Fellow in Medicine, in the Department of Medicine, at Beth Israel Deaconess Medical Center in Boston.
Dr. Aditya Bardia is a professor in the Department of Medicine, Division of Hematology/Oncology, director of Translational Research Integration, and a member Signal Transduction and Therapeutics, at University of California, Los Angeles (UCLA) Health Jonsson Comprehensive Cancer Center.
Image of a woman with light shoulder-length hair, wearing rectangular glasses.
Image of man with grey hair.
Image of woman with blonde hair.
Related Content
An expert discusses the FDA approval of Enhertu in unresectable or metastatic HR+, HER2-low or -ultralow breast cancer: © stock.adobe.com
February 19th 2025

Understanding the FDA Approval of Enhertu in HER2-Low and -Ultralow Breast Cancer

Ryan Scott
Dr. Debu Tripathy breaks down the FDA approval of Enhertu in unresectable or metastatic HR-positive, HER2-low or -ultralow breast cancer.
FDA, Cancer Vaccine Updates and a Misguiding of Breast Cancer Treatment
February 5th 2024

FDA, Cancer Vaccine Updates and a Misguiding of Breast Cancer Treatment

Alex Biese Brielle Benyon
One cancer vaccine may still be years away from being available, a breast cancer test may be misguiding treatments for Black women and the review of two oncology regimens are being expedited by the FDA.
Image of Randy Moss Photo credit: Jonathan Bachman - Getty Images
February 7th 2025

Randy Moss Shares Cancer Update, “Squid Game” Star Dies and More

Alex Biese
From the death of a Netflix actress due to stomach cancer complications to an NFL star sharing his chemo experience, here is this week’s cancer news.
Cancer Horizons podcast logo
December 12th 2023

Conference Highlights from SABCS

Alex Biese Brielle Benyon
CURE® recently covered the San Antonio Breast Cancer Symposium. In case you missed it, here is some news that came out of the conference that patients should know about.
Image of patient with breast cancer and oncologist.
February 4th 2025

A Patient-Centered Approach to Plastic Surgery Reconstruction

SurvivingBreastCancer.org (SBC)
Breast cancer surgery is a deeply personal and often challenging experience for many women.
Image of patients with breast cancer
February 4th 2025

Nutrition After a Cancer Diagnosis

Surviving Breast Cancer
If you’re reading this, you recognize the importance of diet and nutrition after a cancer diagnosis.